The company shared new real-world findings for Aveir DR at the Asia Pacific Heart Rhythm Society (APHRS). These add to strong results for Aveir shared in May.
Aveir DR is the world’s first dual-chamber leadless pacemaker. It treats people with abnormal or slow heart rhythms. The system enables a beat-to-beat, wireless communication channel between two leadless pacemakers. One paces the right ventricle (Aveir VR) and the other paces the right atrium (Aveir AR). Each device comes in at roughly one-tenth the size of a traditional pacemaker — smaller than a AAA battery.
The system delivers electrical impulses directly to the heart muscle, restoring the normal heart rhythm. Unlike traditional pacemakers, the leadless devices go directly into the heart through a minimally invasive, catheter-based procedure. This eliminates the need for cardiac leads and a pulse generator under the skin.
(Read more about Aveir at Medical Design & Outsourcing.)
Aveir DR uses Abbott’s proprietary i2i (implant-to-implant) technology, the system provides synchronized pacing on every heartbeat based on a person’s clinical needs. Abbott announced in July 2023 that it received FDA approval for the dual-chamber pacemaker system. The company completed the first U.S. commercial cases with Aveir DR in November 2023.
Results shared at APHRS showed that Aveir DR delivered safer outcomes compared to traditional transvenous pacemakers. Outcomes included fewer device-related complications, supporting the adoption of leadless pacing technologies. Abbott also believes findings could support future Medicare coverage pathways.
Aveir DR delivered 41% fewer overall chronic complications at six months compared to traditional pacemakers. Investigators also saw 50% fewer device-related complications at 30 days and 52% fewer at six months. Patients had 51% fewer device reinterventions at six months as well.
